Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis

Table 1 Characteristics of the studies included on the use of Infliximab and Adalimumab during pregnancy

Study	Design	Pregnancies (n)	No. of pregnancies in infliximab-exposed group	No. of pregnancies in adalimumab-exposed group	Study quality
Kiely CJ [17]	P	21	10 Infliximab	11 Adalimumab	☆☆☆☆☆☆
Schnitzler F [18]	P	42	35 Infliximab	7 Adalimumab	☆☆☆☆☆☆☆
Seirafi M [19]	P + R	128	86 Infliximab	42 Adalimumab	☆☆☆☆☆☆☆
Casanova MJ [20]	R	29	20 Infliximab	9 Adalimumab	☆☆☆☆☆☆☆
Julsgaard M [21]	P	80	44 Infliximab	36 Adalimumab	☆☆☆☆☆☆
Arsenescu R [22]	R	10	8 Infliximab	2 Adalimumab	☆☆☆☆☆
Slama W [23]	P	186	122 Infliximab	64 Adalimumab	☆☆☆☆☆
Zelinkova Z [24]	P + R	31	18 Infliximab	13 Adalimumab	☆☆☆☆☆☆

ISSN: 1471-2393